Hematology › Forums › Hematology MCQ discussion forum › NEET SS Clinical Hematology 2020 Telegram Group Discussion MCQs › Reply To: NEET SS Clinical Hematology 2020 Telegram Group Discussion MCQs
34. FEIBA is a factor bypass agent ie hemostatic agent used in hemophilia patients with inhibitors. Its components are ?
 Factor II, VII
 Factor II, VII, IX
 Factor II, VII, IX, X
 Factor II, VII, VIII, IX
Answer =  Factor II, VII, IX, X
FEIBA contains mainly non-activated factors II, IX, and X and mainly activated factor VII. It contains approximately equal unitages of factor VIII inhibitor bypassing activity and prothrombin complex factors.
Bypassing agents are presently the standard of care for the treatment of bleeding episodes in patients with hemophilia and high‐titer inhibitors and are also used for bleed prevention. Bypassing agents available to patients are activated prothrombin complex concentrates recombinant factor VIIa and emicizumab (a bispecific antibody that mimics the function of FVIIIa in the intrinsic Xase complex).
Bypassing agents have been the primary therapeutic option for hemophilia patients with high responding inhibitors (titers ≥ 5.0 Bethesda Units).
- This reply was modified 1 year, 11 months ago by Dr Sujeet Kumar.